---
document_datetime: 2023-11-15 10:11:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/rebetol-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: rebetol-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.444394
conversion_datetime: 2025-12-28 00:40:27.448117
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Steps taken after granting the Marketing Authorisation

For procedures finalised after 5 September 2004 please refer to module 8B.

| Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Extension of indication to use ribavirin in combination with peginterferon alfa-2b for the treatment of chronic hepatitis C.                                                                                                                                                                                                                                                                                                                                          | II/0005              | II                       | 14.12.00                            | 26.03.00                                 |
| Quality change (to comply with European TSE Directive and Guidance)                                                                                                                                                                                                                                                                                                                                                                                                   | II/0006              | II                       | 25.04.01                            | -                                        |
| Minor change of Manufacturing process.                                                                                                                                                                                                                                                                                                                                                                                                                                | I/0007               | I                        | 02.03.01                            | -                                        |
| The Marketing Authorisation Holder applied for the addition in the labelling of information on the sustained response rate from the pivotal trial with combination therapy (C/I98-580) in patients with baseline fibrosis. Moreover the information with regard to mitochondrial toxicity and lactic acidosis reported in HIV-positive patients receiving NRTI regimen and co-infected with HCV/HBV has been also included in the SPC through this variation. product | II-0008              | II                       | 15.11.01                            | 12.04.02                                 |
| Quality change (in in-process control specifications)                                                                                                                                                                                                                                                                                                                                                                                                                 | II-0009              | II                       | 18.10.01                            | -                                        |
| This notification relates to address changes affecting the Package Leaflet (Annex IIIB).                                                                                                                                                                                                                                                                                                                                                                              | N-0010               | N                        | 22.10.01                            | 07.02.02                                 |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended for procedures finalised before 1 October 2003. In accordance with Article 6 of Commission Regulation (EC) No 1085/2003 for procedures finalised after 1 October 2003  : I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

路 On 28 May 1999, the Marketing Authorisation Holder submitted to the EMEA two applications for a Type I variation. The first application related to the inclusion of an alternate manufacturing site for ribavirin capsules and the second application related to a minor change of manufacturing process of the active substance. The EMEA approved these variations on 7 July 1999. 路 On  18  February  2000,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application  for  a  Type  I  variation  related  to  a  minor  change  of  manufacturing  process  of  the active substance. The EMEA approved this variation on 24 March 2000. 路 On 5 January 2000, the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  II  variation  related  to  the  update  of  the  Summary  of  Product  Characteristics  and Package  Leaflet  to  include  two  undesirable  effects.  The  CPMP,  during  its  March  plenary meeting,  considered  the  changes  acceptable,  and  adopted  on  16  March  2000  a  favourable opinion  on  the  Type  II  variation.  The  corresponding  Commission  Decision  was  issued  on 24 July 2000. 路 On 9 June 2000, the Marketing Authorisation Holder submitted to the EMEA an application for a  Type  II  variation  related  to  the  extension  of  the  indication  for  ribavirin  to  be  used  in combination with peginterferon alfa-2b for the treatment of chronic hepatitis C. The  CPMP,  during  its  December  plenary  meeting,  considered  the  changes  acceptable,  and adopted on 14 December 2000 a favourable opinion on the Type II variation. The corresponding Commission Decision was issued on 26 March 2001. Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: Medicinal product no longer authorised

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.

<div style=\"page-break-after: always\"></div>

| The MAH applied to add a stand-alone checkweighter machine to be used after the encapsulation process in order to verify the weight of each capsule and to reject those that are outside of the specification ranges.                                                                                                     | I-0012   | I   | 10.04.03   | -            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----|------------|--------------|
| The MAH applied to add an alternative encapsulator equipped with an in-line weight verification system.                                                                                                                                                                                                                   | I-0013   | I   | 10.04.03   | - authorised |
| The MAH applied for an update of Summary of Product Characteristics, to add information on carcinogenicity in sections 4.4 (Special warnings and special precautions for use) and 5.3 (Preclinical safety data) following follow-up measure result of study SCH 18908.                                                    | II-0011  | II  | 26.06.03   | 03.10.03     |
| The MAH applied for a number of changes related to the active substance, ribavirin. These changes involve the synthesis process as well as specifications and test methods. Furthermore, an extension of the shelf life from 1 to 3 years is proposed for ribavirin synthesised by Orgamol (Evionnaz site - Switzerland). | II-0015  | II  | 25.09.03   | -            |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                          | N-0017   | N   | 10.11.03   | -            |
| Renewal of the Marketing Authorisation                                                                                                                                                                                                                                                                                    | R-0019   | R   | 22.04.04   | 02.09.04     |

<!-- image -->